Defendant
1 case as defendant.
Novarad Corp is a private health technology company headquartered in Provo, Utah, though some sources indicate American Fork, Utah. Founded in 1988, the company focuses on enterprise medical imaging and workflow solutions for healthcare providers globally. Novarad is estimated to have approximately 200-400 employees and an estimated annual revenue in the range of $100M-$250M.
Novarad provides a comprehensive suite of medical imaging software and hardware products. Its major offerings include NovaPACS Enterprise Imaging for Picture Archiving and Communication Systems (PACS), NovaRIS for Radiology Information Systems, NovaCardio for cardiology imaging, and NovaMG Pro and MammoIQ for breast imaging and mammography. The company is also notable for its augmented reality (AR) surgical navigation systems, VisAR and OpenSight, which have received FDA clearance and overlay medical images directly onto a patient's body for precision surgery. Additionally, Novarad offers NovaDose for radiation dose monitoring and CryptoChart for secure patient data sharing.
In terms of patent litigation, Novarad Corp appears to operate as an operating company that defends its intellectual property. The company has one tracked case, listed as a defendant in Unified Patents v. Novarad Corp at the Patent Trial and Appeal Board (PTAB). This posture, with zero plaintiff cases and one defendant case, is consistent with an operating company facing a challenge to its patents.
Further context indicates that Novarad actively defends its patent portfolio; in December 2025, the U.S. Court of Appeals affirmed one of Novarad's patents (the '807 patent) related to augmented reality surgical navigation. This suggests the PTAB case may be part of ongoing efforts to challenge or validate patents integral to their key AR surgical navigation products like VisAR.
Unified Patents filed an Inter Partes Review (IPR) against Novarad Corp, the patent owner, challenging US patent 11004271, which resulted in a Final Written Decision.